Clinical Trial Update: Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer [Phase 1]

View source ↗

Summary

The Phase 1 trial evaluates fluciclovine and PSMA PET/CT for classification and improved staging of invasive lobular breast cancer. The study has completed and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Invasive Lobular Carcinoma of the Breast

Drugs mentioned

• 68Ga-PSMA-11 (Gallium-68 labeled PSMA-11 radiopharmaceutical)
• Axumin (fluciclovine F-18)

Snippet

Sponsor: Emory University | Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2025-01-17